Wanbangde Pharmaceutical Holding Group Co Ltd (002082) — Cash Flow-to-Debt Ratio
Wanbangde Pharmaceutical Holding Group Co Ltd (002082) has a Cash Flow-to-Debt Ratio of 0.00x as of September 2025, meaning its operating cash flow of CN¥-1.04 Million could theoretically repay 0% of its total liabilities (CN¥1.78 Billion) in one year. See Wanbangde Pharmaceutical Holding Group C free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Wanbangde Pharmaceutical Holding Group Co Ltd Cash Flow-to-Debt Ratio (2003–2025)
Historical debt coverage capacity for Wanbangde Pharmaceutical Holding Group Co Ltd across 23 annual periods. Also explore 002082 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Wanbangde Pharmaceutical Holding Group Co Ltd (2003–2025)
Year-by-year debt coverage analysis for Wanbangde Pharmaceutical Holding Group Co Ltd. For market capitalisation and broader financial context, see 002082 market cap.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.34x | CN¥603.98 Million | CN¥1.78 Billion | ▲ +342.5% |
| 2024 | 0.08x | CN¥120.22 Million | CN¥1.57 Billion | ▲ +261.5% |
| 2023 | -0.05x | CN¥-72.87 Million | CN¥1.54 Billion | ▲ +72.4% |
| 2022 | -0.17x | CN¥-239.65 Million | CN¥1.40 Billion | ▼ -1364.0% |
| 2021 | 0.01x | CN¥22.09 Million | CN¥1.63 Billion | ▼ -74.8% |
| 2020 | 0.05x | CN¥151.01 Million | CN¥2.80 Billion | ▲ +140.9% |
| 2019 | -0.13x | CN¥-248.69 Million | CN¥1.89 Billion | ▼ -209.1% |
| 2018 | 0.12x | CN¥135.40 Million | CN¥1.12 Billion | ▲ +440.5% |
| 2017 | -0.04x | CN¥-17.60 Million | CN¥496.58 Million | ▼ -103.0% |
| 2016 | 1.19x | CN¥310.71 Million | CN¥261.85 Million | ▲ +1813.3% |
| 2015 | 0.06x | CN¥16.76 Million | CN¥270.28 Million | ▼ -88.7% |
| 2014 | 0.55x | CN¥140.31 Million | CN¥254.69 Million | ▼ -15.1% |
| 2013 | 0.65x | CN¥234.35 Million | CN¥361.07 Million | ▲ +50.2% |
| 2012 | 0.43x | CN¥202.73 Million | CN¥469.09 Million | ▲ +11897.2% |
| 2011 | 0.00x | CN¥-1.44 Million | CN¥392.22 Million | ▼ -100.9% |
| 2010 | 0.43x | CN¥162.26 Million | CN¥380.46 Million | ▲ +92.4% |
| 2009 | 0.22x | CN¥68.13 Million | CN¥307.39 Million | ▼ -72.9% |
| 2008 | 0.82x | CN¥253.06 Million | CN¥309.46 Million | ▲ +3265.4% |
| 2007 | 0.02x | CN¥12.45 Million | CN¥512.51 Million | ▲ +242.8% |
| 2006 | 0.01x | CN¥3.50 Million | CN¥493.85 Million | ▼ -67.9% |
| 2005 | 0.02x | CN¥11.23 Million | CN¥508.84 Million | ▼ -81.1% |
| 2004 | 0.12x | CN¥32.69 Million | CN¥280.48 Million | ▼ -48.7% |
| 2003 | 0.23x | CN¥37.01 Million | CN¥163.05 Million | — |